Article Versions Notes

Elshazly AM, Sinanian MM, Neely V, Chakraborty E, Alshehri MA, McGrath MK, Harada H, Schoenlein PV, Gewirtz DA. BRD4 Inhibition as a Strategy to Prolong the Response to Standard of Care in Estrogen Receptor-Positive Breast Cancer. Cancers. 2023; 15(16):4066. https://doi.org/10.3390/cancers15164066

Elshazly, Ahmed M., Melanie M. Sinanian, Victoria Neely, Eesha Chakraborty, Muruj A. Alshehri, Michael K. McGrath, Hisashi Harada, Patricia V. Schoenlein, and David A. Gewirtz. 2023. "BRD4 Inhibition as a Strategy to Prolong the Response to Standard of Care in Estrogen Receptor-Positive Breast Cancer" Cancers 15, no. 16: 4066. https://doi.org/10.3390/cancers15164066

Elshazly, A. M., Sinanian, M. M., Neely, V., Chakraborty, E., Alshehri, M. A., McGrath, M. K., Harada, H., Schoenlein, P. V., & Gewirtz, D. A. (2023). BRD4 Inhibition as a Strategy to Prolong the Response to Standard of Care in Estrogen Receptor-Positive Breast Cancer. Cancers, 15(16), 4066. https://doi.org/10.3390/cancers15164066